Outcomes of surgery in epithelial ovarian cancer: our experience
Keywords:Epithelial ovarian cancer, Cytoreduction, Survival
Background: Comprehensive surgical staging and surgical cytoreduction is the primary modality of treatment in early and advanced epithelial ovarian cancer respectively, followed by systemic chemotherapy in most of the patients. The aim of the present study was to evaluate the role of surgery and its impact on disease free and overall survival in patients with epithelial ovarian cancer.
Methods: A retrospective analysis of 38 patients of biopsy proven epithelial ovarian cancer was performed. Patient’s demographic data, details of surgical procedure, post-operative complications, histopathological findings, staging and pattern of recurrence were collected from the medical records.
Results: Six (15.8%) patients had early disease (stage I-II) at presentation while 30 (94.7%) patients advanced disease (stage III-IV). Staging laparotomy was done in six (15.8%) patients, primary cytoreduction in eight (21.05%) patients, interval cytoreduction in 17 (81.6%) patients and secondary cytoreduction in two (5.3%) patients. Five (13.2%) patients were inoperable. The median follow up time was in the range of 2 to 56 months (median 26 months). The three years overall survival in advanced stage was 73.74%. Disease free survivals in primary and interval cytoreduction groups were 80% and 58.67% respectively. The disease free survival in patients with optimal cytoreduction was 72.9%.
Conclusions: The present study indicates that in the majority of patients with advanced ovarian cancer, surgery can lead to optimal cytoreduction with acceptable disease-free and overall survival.
Piver MS, Marchetti DL. Potential for cure in ovarian cancer. Compr Ther. 1986;12:13-20.
Alleti GD , Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced stage ovarian cancer. Obstet Gynaecol. 2006;107:77-85.
Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-4.
Eisenkop S, Spirtos NM, Montag T, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47:203-9.
Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278-87.
Zang RY, Zhang ZY, Cai SM, Li ZT, Chen J, Tang MQ, et al. Cytoreductive surgery for stage IV epithelial Ovarian cancer. J Exp Clin Cancer Res. 1999;18:449-54.
Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol. 2006;103:559-64.
Hunter RW, Alexander ND, Soutter NP. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?. Am J Obstet Gynecol. 1992;166:504-11.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-59.
Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974-80.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2014, based on November 2016 SEER data submission, posted to the SEER web site. Bethesda, MD: National Cancer Institute; 2017.
Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1-5.
Van der Burg ME, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332:629-34.
Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, et al. A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol. 2002;21:201.
Romanidis K, Nagorni EA, Halkia E, Pitiakoudis M. The role of cytoreductive surgery in advanced ovarian cancer: The general surgeon's perspective. J BUON. 2014;19:598-604.
Hoffman MS, Griffin D, Tebes S, Cardosi RJ, Martino MA, Fiorica JV, et al. Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol. 2005;193:582-6.
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma-analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131:15-20.
Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC. Advanced ovarian cancer: correlation of histologic grade with response to therapy and survival. Cancer.1980;45:572-81.
Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch WR. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol. 1989;34:88-93.